Greenland Mines (NASDAQ: GRML) is set to sharpen its focus on critical minerals with a series of strategic moves, including the planned spin-off of its biotechnology division in the fourth quarter of 2026. The announcement comes as the company transitions into a dedicated rare earths and critical minerals company, following the formal approval by Nasdaq of its March 2026 transaction, which resolves prior deficiencies and brings the company into full compliance with listing requirements.
The company has also completed its acquisition of the Sarfartoq project in Greenland, following approval by the Government of Greenland on September 1. An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq estimates a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. This underscores the project's potential to become a significant supplier of neodymium-praseodymium (NdPr) oxide, a critical component in permanent magnets used in electric vehicles and wind turbines.
According to Greenland Mines, planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions the company to play a pivotal role in diversifying the global supply chain for rare earth elements, which is currently dominated by China.
The company is also reshaping its board of directors, with Riad El-Dada and Dr. Shalom Hirschman stepping down, and capital markets veteran Jason Hawkins joining as Greenland Mines advances its Sarfartoq and Skaergaard projects. The Skaergaard project, located in southeast Greenland, is a palladium-gold-platinum project that adds to the company's multi-asset portfolio.
Greenland Mines' strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. The company is also advancing its broader North Atlantic Critical Metals Corridor vision, which aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure. This vision aligns with growing Western efforts to secure supply chains for critical minerals, which are essential for national security and the transition to clean energy.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow Greenland Mines to focus solely on its mining and minerals operations. This move is expected to unlock value for shareholders by creating two distinct, pure-play entities, each with its own strategic focus and growth trajectory.
The successful acquisition of Sarfartoq and the positive assessment of the ST1 deposit mark significant milestones for Greenland Mines, as it seeks to become a leading supplier of rare earth elements outside China. The company's ability to secure necessary approvals and comply with Nasdaq listing requirements demonstrates its commitment to corporate governance and operational excellence.
Investors and industry observers will be watching closely as Greenland Mines executes its strategic plan, including the anticipated biotech spin-off and the continued development of its critical minerals projects. The company's progress in Greenland could have far-reaching implications for the global supply of rare earth elements, which are vital to modern technologies and the transition to a low-carbon economy.
For more information on Greenland Mines and its projects, visit the company's newsroom at https://ibn.fm/GRML. Full terms of use and disclaimers are available at https://IBN.ai/Disclaimer.
